普罗布考联合瑞舒伐他汀对血管性痴呆患者的有效性和安全性分析

Analysis of the efficacy and safety of probucol combined with rosuvastatin in patients with vascular dementia

目的采用普罗布考联合瑞舒伐他汀药物治疗血管性痴呆,探讨分析在治疗中的临床疗效及用药安全性。方法选取来本院进行治疗的56例血管性痴呆患者作为研究对象,经随机分两组,分别为治疗组和对照组,各组28例,对照组患者使用瑞舒伐他汀疗法,治疗组患者在此基础上加用普罗布考药物。在治疗后比较对照组和治疗组的临床疗效情况[简易智能状态检测量表(MMSE)和日常生活能力量表(ADL)评分]及对安全性情况。结果与对照组比较,对照组患者的MMSE及ADL均有明显改善,组间治疗效果差异有统计学意义(P<0.05),且治疗组无药物不良反应出现。结论普罗布考联合瑞舒伐他汀药治疗血管性痴呆具有明显效果,加用贝伐单抗进行辅助治疗比单纯使用常规方式治疗临床效果更加显著,不良反应少,在临床中具有广泛的应用价值,值得进一步推广。

Objective To evaluate the clinical efficacy and safety of drug use in the treatment of vascular dementia with probucol combined with rosuvastatin.Methods Fifty-six patients with vascular dementia were randomly divided into treatment group and control group.The patients in the control group were treated with rosuvastatin and the patients in the treatment group on this basis plus probucol drugs.The clinical efficacy of the control group and the treatment group[(MMSE)and the Daily Life Scale(ADL)score]were compared after treatment and the safety status.Results Compared with the control group,MMSE and ADL in the control group were significantly improved,the treatment effect between the two groups was significantly different(P<0.05),and no adverse drug reaction occurred in the treatment group.Conclusion Probucolide combined with rosuvastatin has a significant effect in the treatment of vascular dementia.Addition therapy with bevacizumab is more significant than that of conventional treatment alone.The clinical effect is more remarkable,less adverse reactions,and has wide application value in clinical practice,worthy of further promotion.